Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 246

1.

Correction: Librarians against scientists: Oncotarget's lesson.

Blagosklonny MV.

Oncotarget. 2018 Mar 13;9(19):15167. doi: 10.18632/oncotarget.24692. eCollection 2018 Mar 13.

2.

Librarians against scientists: Oncotarget's lesson.

Blagosklonny MV.

Oncotarget. 2018 Jan 19;9(5):5515-5516. doi: 10.18632/oncotarget.24272. eCollection 2018 Jan 19. No abstract available. Erratum in: Oncotarget. 2018 Mar 13;9(19):15167.

3.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

4.

While reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts.

Leontieva OV, Blagosklonny MV.

Oncotarget. 2017 May 11;8(65):109848-109856. doi: 10.18632/oncotarget.17827. eCollection 2017 Dec 12.

5.

From rapalogs to anti-aging formula.

Blagosklonny MV.

Oncotarget. 2017 May 30;8(22):35492-35507. doi: 10.18632/oncotarget.18033. Review.

6.

Gerosuppression by pan-mTOR inhibitors.

Leontieva OV, Blagosklonny MV.

Aging (Albany NY). 2016 Dec 30;8(12):3535-3551. doi: 10.18632/aging.101155.

7.

Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).

Leontieva OV, Demidenko ZN, Blagosklonny MV.

Oncotarget. 2015 Sep 15;6(27):23238-48.

8.

Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.

Lesovaya EA, Kirsanov KI, Antoshina EE, Trukhanova LS, Gorkova TG, Shipaeva EV, Salimov RM, Belitsky GA, Blagosklonny MV, Yakubovskaya MG, Chernova OB.

Oncotarget. 2015;6(12):9718-27.

9.

Rejuvenating immunity: "anti-aging drug today" eight years later.

Blagosklonny MV.

Oncotarget. 2015 Aug 14;6(23):19405-12.

10.

Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.

Leontieva OV, Blagosklonny MV.

Oncotarget. 2014 Dec 30;5(24):12715-27.

11.

Gerosuppression in confluent cells.

Leontieva OV, Blagosklonny MV.

Aging (Albany NY). 2014 Dec;6(12):1010-8.

12.

Fasting levels of hepatic p-S6 are increased in old mice.

Leontieva OV, Paszkiewicz GM, Blagosklonny MV.

Cell Cycle. 2014;13(17):2656-9. doi: 10.4161/15384101.2014.949150.

13.

Comparison of rapamycin schedules in mice on high-fat diet.

Leontieva OV, Paszkiewicz GM, Blagosklonny MV.

Cell Cycle. 2014;13(21):3350-6. doi: 10.4161/15384101.2014.970491.

14.

Geroconversion: irreversible step to cellular senescence.

Blagosklonny MV.

Cell Cycle. 2014;13(23):3628-35. doi: 10.4161/15384101.2014.985507. Review.

15.

Koschei the immortal and anti-aging drugs.

Blagosklonny MV.

Cell Death Dis. 2014 Dec 4;5:e1552. doi: 10.1038/cddis.2014.520. Review.

16.

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.

Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G.

Cell Death Differ. 2015 Jan;22(1):58-73. doi: 10.1038/cdd.2014.137. Epub 2014 Sep 19. Review.

17.

Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program.

Leontieva OV, Demidenko ZN, Blagosklonny MV.

Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8832-7. doi: 10.1073/pnas.1405723111. Epub 2014 Jun 2.

18.

Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium.

Leontieva OV, Demidenko ZN, Blagosklonny MV.

Cell Death Dis. 2014 May 8;5:e1214. doi: 10.1038/cddis.2014.178.

19.

Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet.

Leontieva OV, Paszkiewicz GM, Blagosklonny MV.

Aging Cell. 2014 Aug;13(4):616-22. doi: 10.1111/acel.12211. Epub 2014 Mar 22.

20.

Immunosuppressants in cancer prevention and therapy.

Blagosklonny MV.

Oncoimmunology. 2013 Dec 1;2(12):e26961. Epub 2013 Nov 6. Review.

21.

Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin.

Popovich IG, Anisimov VN, Zabezhinski MA, Semenchenko AV, Tyndyk ML, Yurova MN, Blagosklonny MV.

Cancer Biol Ther. 2014 May;15(5):586-92. doi: 10.4161/cbt.28164. Epub 2014 Feb 20.

22.

M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue.

Leontieva OV, Blagosklonny MV.

Cell Cycle. 2014;13(4):509-15. doi: 10.4161/cc.27973. Epub 2014 Jan 23.

PMID:
24496328
23.

Selective anti-cancer agents as anti-aging drugs.

Blagosklonny MV.

Cancer Biol Ther. 2013 Dec;14(12):1092-7. doi: 10.4161/cbt.27350. Epub 2013 Nov 27.

24.

TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.

Blagosklonny MV.

Cell Death Dis. 2013 Dec 12;4:e964. doi: 10.1038/cddis.2013.506. Review.

25.

Aging is not programmed: genetic pseudo-program is a shadow of developmental growth.

Blagosklonny MV.

Cell Cycle. 2013 Dec 15;12(24):3736-42. doi: 10.4161/cc.27188. Epub 2013 Nov 15. Review.

26.

Dysregulation of the mTOR pathway in p53-deficient mice.

Leontieva OV, Novototskaya LR, Paszkiewicz GM, Komarova EA, Gudkov AV, Blagosklonny MV.

Cancer Biol Ther. 2013 Dec;14(12):1182-8. doi: 10.4161/cbt.26947. Epub 2013 Nov 1.

27.

S6K in geroconversion.

Leontieva OV, Demidenko ZN, Blagosklonny MV.

Cell Cycle. 2013 Oct 15;12(20):3249-52. doi: 10.4161/cc.26248. Epub 2013 Sep 9.

28.

CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.

Leontieva OV, Blagosklonny MV.

Cell Cycle. 2013 Sep 15;12(18):3063-9. doi: 10.4161/cc.26130. Epub 2013 Aug 22.

29.

Damage-induced aging and perpetual motion.

Blagosklonny MV.

Cell Cycle. 2013 Sep 1;12(17):2709-10. doi: 10.4161/cc.26015. Epub 2013 Aug 5. No abstract available.

30.

Rapamycin extends life- and health span because it slows aging.

Blagosklonny MV.

Aging (Albany NY). 2013 Aug;5(8):592-8.

31.

M(o)TOR of aging: MTOR as a universal molecular hypothalamus.

Blagosklonny MV.

Aging (Albany NY). 2013 Jul;5(7):490-4.

32.

MEK drives cyclin D1 hyperelevation during geroconversion.

Leontieva OV, Demidenko ZN, Blagosklonny MV.

Cell Death Differ. 2013 Sep;20(9):1241-9. doi: 10.1038/cdd.2013.86. Epub 2013 Jul 12.

33.

Rapamycin suppresses brain aging in senescence-accelerated OXYS rats.

Kolosova NG, Vitovtov AO, Muraleva NA, Akulov AE, Stefanova NA, Blagosklonny MV.

Aging (Albany NY). 2013 Jun;5(6):474-84.

34.

MTOR-driven quasi-programmed aging as a disposable soma theory: blind watchmaker vs. intelligent designer.

Blagosklonny MV.

Cell Cycle. 2013 Jun 15;12(12):1842-7. doi: 10.4161/cc.25062. Epub 2013 Jun 12.

35.

Big mice die young but large animals live longer.

Blagosklonny MV.

Aging (Albany NY). 2013 Apr;5(4):227-33.

37.
38.

Answering the ultimate question "what is the proximal cause of aging?".

Blagosklonny MV.

Aging (Albany NY). 2012 Dec;4(12):861-77. Review.

39.

Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet.

Leontieva OV, Paszkiewicz G, Demidenko ZN, Blagosklonny MV.

Cell Death Dis. 2013 Jan 24;4:e472. doi: 10.1038/cddis.2012.202.

40.

Hypoxia, MTOR and autophagy: converging on senescence or quiescence.

Blagosklonny MV.

Autophagy. 2013 Feb 1;9(2):260-2. doi: 10.4161/auto.22783. Epub 2012 Nov 28.

41.

Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells.

Leontieva OV, Lenzo F, Demidenko ZN, Blagosklonny MV.

Cell Cycle. 2012 Dec 15;11(24):4642-9. doi: 10.4161/cc.22937. Epub 2012 Nov 27.

42.

Rapalogs in cancer prevention: anti-aging or anticancer?

Blagosklonny MV.

Cancer Biol Ther. 2012 Dec;13(14):1349-54. doi: 10.4161/cbt.22859. Epub 2012 Nov 14. Review.

43.

Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice.

Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, Blagosklonny MV, Gudkov AV.

Aging (Albany NY). 2012 Oct;4(10):709-14.

44.

New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis.

Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV, Gudkov AV, Antoch MP.

Aging (Albany NY). 2012 Oct;4(10):715-22.

45.

Hypoxia and gerosuppression: the mTOR saga continues.

Leontieva OV, Blagosklonny MV.

Cell Cycle. 2012 Nov 1;11(21):3926-31. doi: 10.4161/cc.21908. Epub 2012 Sep 17.

46.

How to save Medicare: the anti-aging remedy.

Blagosklonny MV.

Aging (Albany NY). 2012 Aug;4(8):547-52.

47.
48.

Hypoxia suppresses conversion from proliferative arrest to cellular senescence.

Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV.

Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13314-8. doi: 10.1073/pnas.1205690109. Epub 2012 Jul 30.

49.

Prospective treatment of age-related diseases by slowing down aging.

Blagosklonny MV.

Am J Pathol. 2012 Oct;181(4):1142-6. doi: 10.1016/j.ajpath.2012.06.024. Epub 2012 Jul 27. Review.

PMID:
22841821
50.

Supplemental Content

Loading ...
Support Center